- Stocks
- Pharma & Healthcare
- Jenburkt Pharma
Jenburkt Pharma share price
NSE: JENBURPHPharma & HealthcareDrug Manufacturers - Specialty & Generic
Jenburkt Pharma at a glance
Jenburkt Pharma (NSE: JENBURPH) closed at ₹914.80 on 21 Oct 2026, up 1.06% on the day. With a market capitalisation of ₹404 Cr, it ranks 1897th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 11.6× trailing earnings, against a return on equity of 18.7% in FY25. Its 52-week range is ₹864.00 (8 Oct 2026) to ₹1,064.00 (31 Aug 2026); the last close is 14.0% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹36 Cr (−0.1% year on year) and net profit ₹6 Cr (−24.4%), on a standalone basis. Promoters held 46.62% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹404 CrRank 1897 on NSE
- P/E (trailing)
- 11.6×
- Price to book
- 2.6×FY25
- EPS (TTM)
- ₹74.39to Q1 FY27
- ROE
- 18.7%FY25
- ROCE
- 25.0%FY25
- Debt to equity
- 0.01FY25
- Net profit margin
- 21.1%FY25
- Book value / share
- ₹389.23FY25
- Dividend payout
- 21.1%FY25
- 52-week high
- ₹1,064.0031 Aug 2026
- 52-week low
- ₹864.008 Oct 2026
- RSI (14-day)
- 41.7
Returns to 21 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +1.06% | −0.4% | −7.0% | — | — |
Jenburkt Pharma quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹41 Cr | ₹37 Cr | ₹41 Cr | ₹36 Cr | ₹46 Cr | ₹43 Cr | ₹45 Cr | ₹36 Cr |
| Revenue YoY | +7.7% | +3.4% | +5.7% | +9.2% | +10.5% | +16.6% | +8.7% | −0.1% |
| Net profit | ₹10 Cr | ₹7 Cr | ₹9 Cr | ₹8 Cr | ₹10 Cr | ₹6 Cr | ₹11 Cr | ₹6 Cr |
| Net profit YoY | +31.1% | +20.6% | +8.4% | +5.0% | +5.8% | −8.9% | +27.0% | −24.4% |
| Net margin | 23.3% | 17.6% | 20.8% | 21.9% | 22.3% | 13.8% | 24.3% | 16.6% |
| EPS | ₹21.75 | ₹14.75 | ₹19.34 | ₹17.66 | ₹23.03 | ₹13.44 | ₹24.58 | ₹13.34 |
Jenburkt Pharma financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹119 Cr | ₹109 Cr | ₹124 Cr | ₹137 Cr | ₹142 Cr | ₹152 Cr |
| Operating profit | ₹21 Cr | ₹22 Cr | ₹30 Cr | ₹33 Cr | ₹35 Cr | ₹44 Cr |
| Net profit | ₹15 Cr | ₹17 Cr | ₹22 Cr | ₹25 Cr | ₹26 Cr | ₹32 Cr |
| EPS (₹) | ₹32.40 | ₹35.96 | ₹48.58 | ₹53.90 | ₹58.86 | ₹72.65 |
| Cash from operations | ₹15 Cr | ₹18 Cr | ₹9 Cr | ₹17 Cr | ₹8 Cr | ₹28 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹80 Cr | ₹98 Cr | ₹117 Cr | ₹122 Cr | ₹145 Cr | ₹172 Cr |
Jenburkt Pharma shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 46.68% | 46.67% | 46.66% | 46.65% | 46.64% | 46.62% |
| Domestic institutions | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% |
| Non-institutions | 53.20% | 53.22% | 53.22% | 53.24% | 53.25% | 53.26% |
Jenburkt Pharma vs peers
The listed Pharma & Healthcare companies nearest to Jenburkt Pharma by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| ALBERTDAVDAlbert David | ₹788.95 | −0.76% | −0.9% | ₹450 Cr | — | — |
| ASARFIAsarfi Hospital | — | — | — | ₹446 Cr | — | — |
| JENBURPHJenburkt Pharma | ₹914.80 | +1.06% | — | ₹404 Cr | 11.6 | — |
| TRANSCHEMTranschem | — | — | — | ₹391 Cr | — | — |
| APPLAptus Pharma | — | — | — | ₹377 Cr | — | — |
| MEDICAMEQMedicamen Biotech | ₹265.00 | −3.05% | −13.6% | ₹359 Cr | 36.7 | — |
| ASTALLTDAstal Lab | — | — | — | ₹358 Cr | — | — |
Ask anything about Jenburkt Pharma
Pivot answers on the live chart with evidence you can check, and tests strategies against JENBURPH's own history. Try: “Why has JENBURPH moved over the last three months?” · “Backtest a 50-day moving-average crossover on JENBURPH over five years” · “Compare JENBURPH with ALBERTDAVD on margins and valuation”
Frequently asked questions about Jenburkt Pharma
What is the share price of Jenburkt Pharma today?
Jenburkt Pharma (NSE: JENBURPH) last closed at ₹914.80 on 21 Oct 2026. Its 52-week high is ₹1,064.00 and its 52-week low is ₹864.00.
What is the market cap of Jenburkt Pharma?
Jenburkt Pharma's market capitalisation is ₹404 Cr (₹404 Cr) at the 21 Oct 2026 close, ranking 1897th among the NSE companies Pivot tracks.
What is the P/E ratio of Jenburkt Pharma?
Jenburkt Pharma trades at a trailing P/E of 11.6.
What is the ROE and ROCE of Jenburkt Pharma?
Return on equity was 18.7% in FY25 and return on capital employed was 25.0% in FY25 (standalone figures).
Is Jenburkt Pharma a debt-free company?
Jenburkt Pharma is close to debt-free: its debt-to-equity ratio was 0.01 in FY25.
What were Jenburkt Pharma's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Jenburkt Pharma reported revenue of ₹36 Cr, −0.1% year on year, and net profit of ₹6 Cr, −24.4% year on year.
What is the shareholding pattern of Jenburkt Pharma?
As of 30 Jun 2026: promoters 46.62%, domestic institutions 0.12%, non-institutions 53.26%.
Who are Jenburkt Pharma's competitors?
The listed Pharma & Healthcare companies closest to Jenburkt Pharma by market cap are Albert David, Asarfi Hospital, Transchem, Aptus Pharma, Medicamen Biotech and Astal Lab.
Is Jenburkt Pharma a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Jenburkt Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on JENBURPH against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 21 Oct 2026 (returns and ratios at the 21 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with J · all NSE stocks · this page as text